Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Oct 18, 2017
SALT LAKE CITY, Oct. 18, 2017 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced the U.S. Food and Drug Administration ("FDA") has scheduled the...
-
Sep 21, 2017
SALT LAKE CITY , Sept. 21, 2017 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that the Patent Trial and Appeal Board ("PTAB") of the United...
-
Sep 20, 2017
SALT LAKE CITY, Sept. 20, 2017 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that the Bone, Reproductive and Urologic Drugs Advisory Committee ("
-
Sep 19, 2017
SALT LAKE CITY, Sept. 19, 2017 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, announced today that Dr. Mahesh Patel, Chairman, President and CEO, will provide...
-
Sep 5, 2017
SALT LAKE CITY, Sept. 05, 2017 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, announced today that Dr. Mahesh Patel, Chairman, President and CEO, will provide...
-
Aug 14, 2017
SALT LAKE CITY, Aug. 14, 2017 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that the U.S. Food & Drug Administration ("FDA") has acknowledged...
-
Aug 9, 2017
SALT LAKE CITY, Aug. 09, 2017 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced the resubmission of a New Drug Application ("NDA") for LPCN 1021,...
-
Aug 7, 2017
SALT LAKE CITY, Aug. 07, 2017 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced financial results for the three and six months ended June 30,...
-
Aug 2, 2017
SALT LAKE CITY, Aug. 02, 2017 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, announced today that Dr. Mahesh Patel, Chairman, President and CEO, will provide...
-
Jun 26, 2017
SALT LAKE CITY, June 26, 2017 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that it has submitted a Special Protocol Assessment ("SPA")...
-
Jun 19, 2017Conference Call and Webcast Scheduled for 5:00 p.m. Eastern Time
SALT LAKE CITY, June 19, 2017 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that the Company will host a conference call and webcast today,...
-
Jun 19, 2017LPCN 1021 achieved primary endpoints confirming the efficacy of twice daily oral administration
SALT LAKE CITY, June 19, 2017 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced results from both the Dosing Validation ("DV") and the Dosing...
-
Jun 15, 2017Consistent and predictable therapeutic levels of testosterone when administered with a meal
SALT LAKE CITY, June 15, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced the successful completion of its labeling "food effect study" for...
-
Jun 2, 2017
SALT LAKE CITY, June 02, 2017 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, announced today that Dr. Mahesh Patel, Chairman, President and CEO, and Morgan...
-
May 8, 2017
SALT LAKE CITY, May 08, 2017 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced financial results for the first quarter ended March 31, 2017....
-
Apr 24, 2017Top-line data from the studies expected in June 2017
SALT LAKE CITY, April 24, 2017 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced the completion of enrollment for both its dosing validation...
-
Mar 28, 2017
SALT LAKE CITY, March 28, 2017 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that Mahesh Patel, President and CEO, and Morgan Brown,...
-
Mar 6, 2017
SALT LAKE CITY, March 06, 2017 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that Mahesh Patel, President and CEO, and Morgan Brown,...
-
Mar 6, 2017
SALT LAKE CITY, March 06, 2017 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced financial and operational results for the full year ended...
-
Feb 15, 2017
SALT LAKE CITY, Feb. 15, 2017 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company focused on developing innovative oral treatment alternatives for use in men's and...
-
Feb 14, 2017
SALT LAKE CITY, March 14, 2017 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that Mahesh Patel, President and CEO, and Morgan Brown,...
-
Jan 9, 2017
Critical Phase 3 study design input received from U.S. Food and Drug Administration ("FDA"): Agreed to a randomized open-label, two-arm clinical study to include a LPCN 1107 arm and a comparator...
-
Jan 5, 2017
SALT LAKE CITY, Jan. 05, 2017 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced plans to initiate a dosing flexibility ("DF") study in addition...
-
Dec 5, 2016
SALT LAKE CITY, Dec. 05, 2016 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced it plans to initiate a dosing validation study after receiving...
-
Nov 8, 2016
SALT LAKE CITY, Nov. 08, 2016 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced financial and operational results for the quarter ended September...